Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Stanford University
Information provided by (Responsible Party):
Stanford University Identifier:
First received: July 5, 2006
Last updated: August 28, 2014
Last verified: August 2014

July 5, 2006
August 28, 2014
January 2002
January 2022   (final data collection date for primary outcome measure)
Biomarkers for disease [ Time Frame: Day one ] [ Designated as safety issue: No ]
Survival analysis and response to anti-cancer therapy
Complete list of historical versions of study NCT00349830 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA


Non-Probability Sample

cancer patients

  • Carcinomas (Including Squamous Cell and Adenocarcinoma)
  • Neoplasms
Procedure: blood draw
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
January 2022   (final data collection date for primary outcome measure)
  1. Age > or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled.
  2. Prior diagnosis of cancer or suspected of having cancer
  3. Karnofsky performance status of greater than 70
  4. Standard pretreatment evaluation
  5. Signed Stanford University Human Subjects Committee consent
18 Years and older
United States
VAR0006, 77923
Not Provided
Stanford University
Stanford University
Not Provided
Principal Investigator: Albert Koong Stanford University
Stanford University
August 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP